Covidien CFO Joins Haemonetics’ Board

Braintree, Mass.-based Haemonetics Corporation has invited Charles J. Dockendorff by election to sit on its board of directors. Dockendorff, is executive vice president and chief financial officer (CFO) of Covidien plc, a position he has held since 1995. He is responsible for Covidien’s financial management activities including corporate accounting, tax, treasury, financial planning, investor relations, internal audit and information services, and he oversees the financial leadership of Covidien’s three business segments.

Dockendorff joined Kendall Healthcare Products Company, the foundation of Covidien formerly known as Tyco Healthcare, in 1989 as controller and he was named vice president and controller in 1994. He was appointed CFO of Covidien 1995 and held that position throughout the company’s growth from $600 million in revenue to a diverse $10 billion healthcare products leader.

Before joining Covidien and its predecessors, Dockendorff was CFO, vice president of finance and treasurer of Epsco Inc. and the CFO of Infrared Industries Inc. His early career included accounting positions with Arthur Young & Company (now Ernst & Young) and General Motors Corporation. He is a CPA (certified public accountant) and has a bachelor’s degree in business administration/accounting from the University of Massachusetts and a master of science degree in finance from Bentley College.

“Chuck is a highly-respected healthcare industry leader,” said Chairman of the Board Richard J. Meelia. “He brings an extensive financial management and planning background to our board, along with considerable experience with one of the world’s premier healthcare products companies. His contributions will help to guide the company as it seeks to grow market share and provide industry leading returns to shareholders.”

“Blood management is a key element of the health care continuum globally, as patient care advances and the focus on reducing costs continues to be a priority. Haemonetics is very well positioned with solutions to help our collection and hospital customers address these opportunities,” said Dockendorff. “I look forward to joining the board of directors and serving the company’s shareholders.”

Haemonetics is a blood management solutions provider.